MAP2K1 and cancer: Cancer cell lines harboring mutations in BRAF were on average three times more sensitive than cell lines expressing wild-type BRAF. Mutant BRAF is also a predictive biomarker of drug response for B-RAF and MEK1 inhibitors profiled in our cancer cell line panel (4, 6).